Mereo Biopharma Group Plc (MREO) Price & Analysis

Compare

700 Followers

MREO Stock Chart & Stats

$1.96

-$0.02(-0.40%)

At close: Jan 08 4:00 PM EST

$1.96

-$0.02(-0.40%)

Day’s Range― - ―

52-Week Range$1.47 - $3.94

Previous CloseN/A

Volume219.93K

Average Volume (3M)1.44M

Market Cap

$278.42M

Enterprise Value$281.28M

Total Cash (Recent Filing)$48.70M

Total Debt (Recent Filing)$397.00K

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Apr 01, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding159,131,700

10 Day Avg. Volume1,197,572

30 Day Avg. Volume1,435,505

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)8.49

Price to Sales (P/S)0.00

P/FCF Ratio-15.44

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue562.55

Enterprise Value/Gross Profit2.94K

Enterprise Value/Ebitda-6.47

Forecast

1Y Price Target

$7.00

Price Target Upside257.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.05

Revenue Forecast (FY)$20.60M

Bulls Say, Bears Say

Bulls Say

Commercial OpportunityIn case of a positive readout, the commercial opportunity for setrusumab could be transformative for the stock, as it would enter an unserved market.

Statistical ThresholdA more permissive statistical threshold, improving the chance of significance at the final analysis.

Treatment EfficacyLonger treatment allows setrusumab’s dual action to gradually increase BMD, reducing fracture risk over time.

Bears Say

Interim Analysis ResultsBoth the IA1 in January and IA2 mid-year were unsuccessful.

Mereo Biopharma Group Plc News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Reviva Pharmaceuticals Holdings (RVPH)...

10d ago

QSI

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: VisionWave Holdings Inc (VWAV)...

13d ago

BTQ

ITB

Mereo BioPharma reports Q3 EPS (1c), consensus 0c

“We are rapidly approaching a major transition period in our corporate evolution, with the Phase 3 Orbit and...

24d ago

MREO

Mereo BioPharma’s Q3 2025: Progress in Rare Disease Pipeline

Mereo Biopharma ( ($MREO) ) has released its Q3 earnings. Here is a breakdown of the information Mereo...

22d ago

MREO

Positive Outlook for Mereo Biopharma: Buy Rating on Promising Setrusumab Developments and Strong Financial Position

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma...

23d ago

MREO

Positive Outlook for Mereo Biopharma Group Plc Driven by Strong Clinical Progress and Strategic Initiatives

Gil Blum, an analyst from Needham, maintained the Buy rating on Mereo Biopharma Group Plc. The associated price...

23d ago

MREO

Mereo BioPharma price target raised to $8 from $7 at JPMorgan

JPMorgan raised the firm’s price target on Mereo BioPharma (MREO) to $8 from $7 and keeps an Overweight...

3M ago

MREO

Mereo Biopharma Group Plc: Strategic Advancements and Promising Developments Justify Buy Rating

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Mereo Biopharma Group Plc on August 12 and...

4M ago

MREO

Promising Future for Mereo Biopharma: Buy Rating Backed by Positive Trial Prospects and Strong Market Position

Analyst Julian Harrison of BTIG maintained a Buy rating on Mereo Biopharma Group Plc, retaining the price target...

4M ago

MREO

Mereo BioPharma Reports Increased Losses Amid Strategic Focus

Mereo Biopharma ( ($MREO) ) has released its Q2 earnings. Here is a breakdown of the information Mereo...

4M ago

MREO

Positive Outlook for Mereo Biopharma Group Plc: Buy Rating Supported by Strong Financial Position and Promising Study Results

Analyst Gil Blum from Needham maintained a Buy rating on Mereo Biopharma Group Plc and keeping the price...

4M ago

MREO

Mereo BioPharma reports Q2 EPS (2c), consensus (1c)

“We look forward to the final analysis for the two ongoing Phase 3 studies for setrusumab in osteogenesis...

4M ago

MREO

Mereo BioPharma sees cash runway into 2027

As of June 30, 2025, the Company had cash and cash equivalents of $56.1 million, compared to $69.8...

4M ago

MREO

Mereo BioPharma’s Setrusumab Study: A Potential Breakthrough for Osteogenesis Imperfecta

Mereo BioPharma (LSE) (($GB:MPH)), Mereo Biopharma (($MREO)) announced an update on their ongoing clinical study. Mereo BioPharma, in...

4M ago

MREO

MREO FAQ

What was Mereo Biopharma Group Plc’s price range in the past 12 months?

Mereo Biopharma Group Plc lowest stock price was $1.47 and its highest was $3.94 in the past 12 months.

What is Mereo Biopharma Group Plc’s market cap?

Mereo Biopharma Group Plc’s market cap is $278.42M.

When is Mereo Biopharma Group Plc’s upcoming earnings report date?

Mereo Biopharma Group Plc’s upcoming earnings report date is Apr 01, 2026 which is in 118 days.

How were Mereo Biopharma Group Plc’s earnings last quarter?

Mereo Biopharma Group Plc released its earnings results on Nov 10, 2025. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.006 by -$0.004.

Is Mereo Biopharma Group Plc overvalued?

According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mereo Biopharma Group Plc pay dividends?

Mereo Biopharma Group Plc does not currently pay dividends.

What is Mereo Biopharma Group Plc’s EPS estimate?

Mereo Biopharma Group Plc’s EPS estimate is 0.

How many shares outstanding does Mereo Biopharma Group Plc have?

Mereo Biopharma Group Plc has 159,131,700 shares outstanding.

What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?

Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.006. Following the earnings report the stock price went up 5.65%.

Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?

Currently, no hedge funds are holding shares in MREO

Mereo Biopharma Group Plc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-69.98%

Trailing 12-Months

Asset Growth

-39.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mereo Biopharma Group Plc

Mereo BioPharma Group Plc (MREO) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of rare and specialty diseases. The company's pipeline includes multiple clinical-stage programs across various therapeutic areas such as oncology, respiratory, and rare diseases. Mereo BioPharma aims to address unmet medical needs through its proprietary drug candidates, leveraging strategic partnerships and collaborations to advance its research and development efforts.

Mereo Biopharma Group Plc (MREO) Earnings & Revenues

Historic Earnings Reports

MREO Stock 12 Month Forecast

Average Price Target

$7.00

▲(257.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","10":"$10","2.5":"$2.5","7.5":"$7.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.5,5,7.5,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.9,2.446153846153846,2.9923076923076923,3.5384615384615383,4.084615384615384,4.63076923076923,5.176923076923076,5.723076923076922,6.269230769230768,6.815384615384614,7.36153846153846,7.907692307692306,8.453846153846154,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.9,2.292307692307692,2.6846153846153844,3.0769230769230766,3.4692307692307693,3.861538461538461,4.253846153846154,4.646153846153846,5.038461538461538,5.430769230769231,5.823076923076923,6.215384615384615,6.607692307692307,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.9,2.1384615384615384,2.376923076923077,2.6153846153846154,2.853846153846154,3.092307692307692,3.3307692307692305,3.569230769230769,3.8076923076923075,4.046153846153846,4.2846153846153845,4.523076923076923,4.7615384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.45,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >